Business Context and Reporting Period
This Form 8-K Current Report from Syndax Pharmaceuticals Inc. covers events occurring on February 6, 2017, with an effective date for key personnel changes on February 13, 2017. The filing primarily addresses the appointment of a new Chief Financial Officer (CFO), the resignation of the outgoing CFO, and the approval of executive compensation packages for 2016 and 2017.
Key Financial Metrics and Compensation
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it details specific compensation figures for executive officers:
- New CFO (Richard P. Shea): Annual base salary of $325,000; target bonus of 35% of base salary; one-time option grant for 125,000 shares.
- CEO (Briggs W. Morrison): 2016 cash bonus of $244,250; 2017 base salary of $549,585; 2017 bonus target of 40%; option grant for 160,000 shares.
- President/COO (Michael A. Metzger): 2016 cash bonus of $218,500; 2017 base salary of $491,625; 2017 bonus target of 40%; option grant for 95,000 shares.
- CMO (Michael L. Meyers): 2016 cash bonus of $152,500; 2017 base salary of $400,000; 2017 bonus target of 35%; option grant for 66,100 shares.
Stock options granted to executives have an exercise price of $8.77 per share and vest monthly over 48 months.
Material Changes
The primary material change is the leadership transition in the finance function:
- Departure: Alan L. Shaw resigned as CFO, Treasurer, Principal Financial Officer, and Principal Accounting Officer effective February 13, 2017.
- Appointment: Richard P. Shea, a former board member, was appointed CFO, Principal Financial Officer, Principal Accounting Officer, and Treasurer effective February 13, 2017.
- Board Changes: Mr. Shea resigned from the Board of Directors and as Chairman of the Audit Committee. Pierre Legault was appointed as the new Chairman of the Audit Committee.
Outlook, Risks, and Unusual Items
The filing contains no forward-looking guidance regarding product development, clinical trials, or financial projections. Key contractual terms and contingencies include:
- Severance Provisions: Both the incoming and outgoing CFOs have agreements providing for severance payments (6 months base salary for termination without cause) and accelerated vesting of equity awards under specific conditions.
- Change in Control: Enhanced severance benefits (12 months base salary plus bonus) and full accelerated vesting apply if employment is terminated around a "change in control" event.
- Golden Parachute: The agreement includes a "gross-up" provision to cover excise taxes if severance payments are deemed parachute payments under Section 280G of the Code.
Investor Verification Checklist
- Verify the stock price on February 13, 2017, to confirm the exercise price for Richard P. Shea's 125,000 share option grant.
- Review the full text of the Employment Agreement (to be filed in the Q1 2017 Form 10-Q) for detailed definitions of "cause" and "good reason."
- Confirm the transition timeline, noting that the outgoing CFO, Alan L. Shaw, remains through February 28, 2017.
- Monitor future filings for the impact of the new CFO on financial reporting and capital strategy.